Prevalence and Risk Factors for Acute Kidney Injury Associated with Parenteral Polymyxin B Use^(December)

¹ Assistant Professor, Internal Medicine Department, Division of Internal Medicine, Hospital de Base, São José do Rio Preto Medical School, São José do Rio Preto, São Paulo, Brazil
² Professor of Statistics, Epidemiology and Public Health Department, São José do Rio Preto Medical School
³ Professor of Medicine, Division of Nephrology, Hospital de Base, São José do Rio Preto Medical School

^* To whom correspondence should be addressed. E-mail: burdmann{at}famerp.br.

	Abstract

BACKGROUND: The main adverse effect of polymyxin B is nephrotoxicity. There are few data on polymyxin-associated renal injury.

OBJECTIVE: To assess the prevalence of and risk factors for acute kidney injury (AKI) in patients treated with polymyxin B.

METHODS: The studied population included 114 patients who received at least 3 consecutive days of intravenous polymyxin B and had baseline serum creatinine (SCr) and at least one further SCr measurement during treatment. AKI was defined as an SCr increase to 1.8 mg/dL or greater in patients with baseline SCr less than 1.5 mg/dL, or an increase greater than or equal to 50% in baseline SCr when it was already greater than or equal to 1.5 mg/dL, or need for dialysis.

RESULTS: AKI developed in 22% of the patients. They were older, had a higher baseline SCr, had a higher frequency of baseline SCr greater than or equal to 1.5 mg/dL, used other nephrotoxic drugs and furosemide more often, and required vasoactive drugs and mechanical ventilation more frequently. Progression to renal failure was significantly more probable when the bacteria were isolated in the abdomen, catheter, or blood. AKI patients had a higher mortality rate (92% vs 53%; p < 0.001). Logistic regression identified abnormal baseline SCr (odds ratio [OR] 3.51); need for vasoactive drugs (OR 3.03); and abdomen, blood, or catheter as the infection site (OR 3.82) as independent risk factors for AKI.

CONCLUSIONS: Patients who developed AKI had a strikingly elevated mortality rate. Polymyxin B should be used with extreme caution in patients who have an abnormal baseline SCr; use vasoactive drugs; or have abdomen, blood, or catheter as the infection site.

Key Words: acute kidney injury, nephrotoxicity, polymyxin B.

Reprints:Dr. Burdmann, São José do Rio Preto Medical School, Av. Brigadeiro Faria Lima, 5416, São José do Rio Preto, São Paulo, Brazil 15090-000, fax 55-17-32162227, burdmann@famerp.br